AQXP | tickerfilter.com

Fundamental analysis

52%

Profitability 71%

Dept financing 2%

Liquidity 50%

Performance 45%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0 0%

1 Month

0 0%

3 Months

0 0%

6 Months

0 0%

1 Year

0 0%

2 Year

0 0%

Key data

Stock price

$3.68

P/E Ratio

N/A

DAY RANGE

$3.68 - $3.68

EPS

-$0.94

52 WEEK RANGE

$2.00 - $3.84

52 WEEK CHANGE

$13.23

MARKET CAP

86.616 M

YIELD

N/A

SHARES OUTSTANDING

23.537 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.00

PUBLIC FLOAT

$23,460,952

AVERAGE 10 VOLUME

$361,693

AVERAGE 30 VOLUME

$183,552

Company detail

CEO: David J. Main
Region: US
Website: http://www.aqxpharma.com
Employees: 8
IPO year: -

Issue type: Common Stock
Market: NASDAQ
Industry: Biotechnology
Sector: Health Technology

Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada.

AQXP - Aquinox Pharmaceuticals Inc.